To the full analysis
Alignment Healthcare stock: growth
ALHCAlignment Healthcare reported $3.95B in revenue for fiscal 2025, up 46.1% on the prior year, up 32.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
31.7%
per year from 2019 to 2025, per share 26%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 32.7% | 31.7% |
| Revenue per share | 31.2% | 26.0% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $756.96M | −$44.73M | −$1.04M |
| 2020 | $959.22M | −$22.93M | −$8.15M |
| 2021 | $1.17B | −$195.29M | −$97.14M |
| 2022 | $1.43B | −$149.55M | −$69.2M |
| 2023 | $1.82B | −$148.02M | −$95.18M |
| 2024 | $2.7B | −$128.04M | −$6.65M |
| 2025 | $3.95B | −$724K | $113.15M |
Revenue by segment
How Alignment Healthcare, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Health Care, Premium91%
- Health Care Capitation7%
- Other1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | Share 2023 | |
|---|---|---|---|---|
| Health Care, Premium | $1.12B | $1.37B | $1.67B | 91.5% |
| Health Care Capitation | $46.22M | $59.22M | $132.8M | 7.3% |
| Other | $0 | $0 | $22.7M | 1.2% |
| Total revenue | $1.17B | $1.43B | $1.82B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.